Dataset from A Randomized, Controlled, Open-Label, Multicenter Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Versus Temsirolimus in Subjects With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00009948
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to evaluate the efficacy and safety of ibrutinib versus
temsirolimus in patients with relapsed or refractory mantle cell lymphoma who received at
least 1 prior chemotherapy regimen.
创建时间：
2025-02-10
